| abstract |
The present invention relates to a receptor binding domain of IgE-dependent histamine releasing factor (HRF) and uses thereof, and more specifically, as an HRF framework region, an FL domain that binds to a receptor of HRF present in a cell membrane, and By confirming the H2 domain, confirming the C-terminus of the HRF, and confirming that the substance binding to it inhibits IL-8 secretion, the domains of FL and H2 and the C-terminus are malaria, asthma, bronchi Inflammation, chronic obstructive pulmonary disease, bronchiectasis, rhinitis, atopic dermatitis, hives, hay fever, conjunctivitis, anaphylactic allergic disease, pneumonia, arthritis, nephritis, psoriasis, dermatitis, Crohn's disease, Enteritis, gingivitis, arteriosclerosis, coronary arteritis, hepatitis, Behcet's disease, bladder cancer, prostatitis, pyelonephritis, glomerulonephritis, osteomyelitis, thyroiditis, grape That it can be used in the development of therapeutic and preventive agents for HRF-related diseases including inflammatory diseases such as inflammation, intraperitoneal inflammation, meningitis, pulmonary fibrosis and rheumatoid arthritis, and screening methods for HRF-related diseases Identify. [Selection] Figure 4 |